Artificial intelligence as a tool for cognitive impairment screening: Patient perspectives about benefits and limitations
Alzheimer's & Dementia: Behavior & Socioeconomics of Aging · 2025
DOI: 10.1002/bsa3.70005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia: Behavior & Socioeconomics of Aging, 2025. Verfasst von Heather M Wurtz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anthropology and Human Rights Institute, University of Connecticut, Storrs, Connecticut, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, National Institute on Aging.
Abstract (Originalsprache)
Introduction
This paper presents findings from a qualitative study exploring the perspectives of primary care patients on the use of artificial intelligence (AI) to synthesize data from the electronic medical record (EMR) and audio recordings of patient speech as a way to detect cognitive impairment.
Methods
We conducted qualitative interviews with a racially and educationally diverse sample of primary care patients ( N = 31) from a large healthcare system in New York City, New York. Interviews focused on the use of AI to synthesize data from the EMR and audio recordings of patient speech. Data were analyzed using content analysis.
Results
Participants reported that AI technology could improve diagnostic accuracy and avoid human errors in the evaluation and diagnosis of cognitive impairment, while also improving clinical efficiency for clinicians. They also expressed concerns about the use of AI tools for screening, such as risk of misdiagnosis, loss of confidentiality, and psychological distress from learning of detected cognitive impairment.
Conclusion
The perceived benefits reported by participants regarding the use of AI screening tools suggest that some patients might support the provision of AI screening in clinical settings. However, participants’ concerns about the potential harms of AI screening tools underscore the need for clear and transparent communication about how results are generated and interpreted. Clinicians need training and other forms of structural support to improve their literacy in AI‐driven tools and their ability to integrate adequate approaches to information sharing into clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anthropology and Human Rights Institute, University of Connecticut, Storrs, Connecticut, USA.
- Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
- Department of Health Policy and Behavioral Sciences, School of Public Health, Georgia State University, Atlanta, Georgia, USA.
- Division of General Internal Medicine, Icahn School of Medicine at Mt. Sinai, New York, New York, USA.
ORCID-Profile: Margaret Manchester
Förderung
- NIA NIH HHS
- National Institute on Aging
Zitieren
APA
Wurtz, H. M., Manchester, M., Valteau, T., Hanson, H., Scipion, C., Federman, A., & Arias, J. J. (2025). Artificial intelligence as a tool for cognitive impairment screening: Patient perspectives about benefits and limitations. Alzheimer's & Dementia: Behavior & Socioeconomics of Aging. https://doi.org/10.1002/bsa3.70005
Vancouver
Wurtz HM, Manchester M, Valteau T, Hanson H, Scipion C, Federman A, et al. Artificial intelligence as a tool for cognitive impairment screening: Patient perspectives about benefits and limitations. Alzheimer's & Dementia: Behavior & Socioeconomics of Aging. 2025. doi:10.1002/bsa3.70005
BibTeX
@article{Wurtz2025,
author = {Wurtz, Heather M and Manchester, Margaret and Valteau, Tatyana and Hanson, Hannah and Scipion, Catherine and Federman, Alex and Arias, Jalayne J},
title = {Artificial intelligence as a tool for cognitive impairment screening: Patient perspectives about benefits and limitations},
journal = {Alzheimer's & Dementia: Behavior & Socioeconomics of Aging},
year = {2025},
doi = {10.1002/bsa3.70005}
}
EUVIMED